



Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type-2 diabetes mellitus and hypertension

Journal:	<i>Blood Pressure</i>
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Olsen, Eirik; St Olavs Hospital University Hospital in Trondheim Holzhauer, Björn; Novartis AG Julius, Stevo; University of Michigan Health System Kjeldsen, S. E.; Oslo universitetssykehus Ulleval, Larstorp, Anne Cecilie; Oslo universitetssykehus Ulleval, Department of Medial Biochemistry; Oslo universitetssykehus Ulleval, Section of Cardiovascular and Renal Research Mancia, Giuseppe; IRCCS Istituto Auxologico Italiano, University of Milano-Bicocca Mehlum, Maria; Oslo University Hospital Ullevaal, Department of Geriatric Medicine Mo, Rune; St. Olav Ways, Cardiology Rostrup, Morten; Oslo University Hospital Ullevaal Søraas, Camilla; Oslo universitetssykehus Ulleval Zappe, Dion; Novartis Pharmaceuticals Corp Weber, Michael A; SUNY Stony Brook
Keywords:	Antihypertensive treatment, blood pressure, blood pressure target, cardiovascular disease, cardiovascular risk, diabetes mellitus, hypertension

SCHOLARONE™
Manuscripts

1
2
3 BLOOD PRESSURE “Back-to-back” ORIGINAL ARTICLE I:
4
5

6 **Cardiovascular outcomes at recommended blood pressure targets in**
7
8
9 **middle-aged and elderly patients with type-2 diabetes mellitus and**
10
11 **hypertension**
12
13
14

15 Eirik Olsen, Björn Holzhauer, Stevo Julius, Sverre E. Kjeldsen, Anne Cecilie K. Larstorp,
16 Giuseppe Mancia, Maria H. Mehlum, Rune Mo, Morten Rostrup, Camilla L. Søråas, Dion
17 Zappe and Michael A. Weber
18
19

20
21 From the Department of Cardiology, St. Olav’s Hospital, and University of Trondheim (E.O.,
22 R.M.), Trondheim, Norway; Novartis Pharma AG (B.H.), Basel, Switzerland; Division of
23 Cardiovascular Medicine (S.J., S.E.K.), University of Michigan, Ann Arbor, MI, USA;
24 Departments of Cardiology and Nephrology (S.E.K.), Medical Biochemistry (A.C.K.L.),
25 Geriatrics (M.H.M.), Acute Medicine (M.R.), Unit of Environmental and Occupational
26 Medicine (C.L.S.) and Cardiovascular & Renal Research Center (S.E.K., A.C.K.L., M.R.,
27 C.L.S.), Oslo University Hospital, Ullevaal, and Faculty of Medicine, Institute of Clinical
28 Medicine (S.E.K., A.C.K.L.) and Department of Behavioural Medicine, Institute of Basic
29 Medical Sciences (M.R.), University of Oslo, Oslo, Norway; Department of Medicine and
30 Surgery (G.M.), University of Milano-Bicocca, Milan, Italy; Novartis Pharma (D.Z.), East
31 Hanover, NJ, USA; and Department of Cardiovascular Medicine (M.A.W.), State University
32 of New York, Downstate College of Medicine, NY, USA
33
34
35
36
37
38
39
40
41
42
43
44

45 CONTACT Sverre E. Kjeldsen (s.e.kjeldsen@medisin.uio.no) Department of Cardiology,
46 Oslo University Hospital, Ullevaal, Oslo N-0407, Norway.
47
48
49
50
51

52 **Word Count:** 238 (abstract) + 2652 (main text) + 21 ref. + 2 tabl. + 2 fig.
53
54
55
56
57
58
59
60

ABSTRACT

Purpose: Available data of event-based clinical outcomes trials show that little evidence supports the guidelines recommendations to lower blood pressure (BP) to $< 130/80$ mmHg in middle-aged and elderly people with type-2 diabetes mellitus (DM) and hypertension. We addressed this issue by post-hoc analyzing the risk of cardiovascular (CV) events in mostly elderly high-risk hypertensive patients with type-2 DM participating in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.

Material and methods: Patients ($n=5250$) were divided into 4 groups according to the proportion of on-treatment visits before the occurrence of an event ($< 25\%$ to $\geq 75\%$) in which BP was reduced to $< 140/90$ or $< 130/80$ mmHg.

Results: After adjustment for baseline demographic differences between groups, a reduction in the proportion of visits in which BP achieved $< 140/90$ mmHg accompanied a progressive increase in the risk of CV mortality and morbidity as well as of cause-specific events such as stroke, myocardial infarction and heart failure. A progressive reduction in the proportion of visits in which BP was reduced $< 130/80$ mmHg did not have any effect on CV risks.

Conclusion: In mostly elderly high-risk hypertensive patients with type-2 diabetes mellitus participating in the VALUE trial, achieving more frequently BP $< 140/90$ mmHg showed a marked protective effect on overall and all cause specific cardiovascular outcomes. This was not the case for a more frequent achievement of the more intensive BP target, i.e. $< 130/80$ mmHg.

KEYWORDS

Antihypertensive treatment; blood pressure; blood pressure target; cardiovascular disease; cardiovascular risk; diabetes mellitus; hypertension

Introduction

Randomized event-based clinical outcomes trials [1-4] show little evidence to support the recommendations of diabetes and hypertension guidelines [5-7] that in patients with type-2 diabetes mellitus (DM) and hypertension, blood pressure (BP) should be treated to < 130/80 mmHg rather than < 140/90 mmHg. While in patients with diabetes, BP reductions to 130-139 mmHg systolic and 80-89 mmHg diastolic have usually been accompanied by reductions in cardiovascular (CV) and renal events, but on-treatment BP values < 130/80 mmHg have usually shown no further protective effect as recently shown in a meta-analysis [8]. This has been found also in post-hoc analyses of trials showing that in diabetes BP reductions < 130/80 mmHg did not provide further CV or renal benefits than those obtained by reducing BP to < 140/90 mmHg. Indeed, in some instance a trend to an increased CV outcome appeared [9-11]. Thus, the optimal target BP has not been settled in patients with diabetes and hypertension, and this is particularly the case in the many elderly patients with the combinations of these diseases.

In the present study we investigated mostly elderly patients with type-2 DM and hypertension in the large database provided by the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial [12]. We aimed to test the hypothesis put forward in recent guidelines [5-7] that achieving a target BP < 130/80 mmHg leads to a lower incidence of CV morbidity and mortality than achieving a target BP < 140/90 mmHg in this population.

Material and methods

Participants

The design and the main results of the VALUE trial have been reported in detail previously [12]. Briefly, VALUE was a multicenter, randomized, double-blind trial which compared the long-term effect of an antihypertensive treatment based on the angiotensin receptor blocker valsartan or the calcium antagonist amlodipine on cardiac morbidity and mortality in hypertensive patients of any ethnicity with an age ≥ 50 years and a high CV risk profile. The qualifying risk factors for recruitment were predefined combinations of male gender, age and other risk factors or the presence of ECG-based left ventricular hypertrophy (with or without a strain pattern), proteinuria, increased serum creatinine, diabetes or a verified but stable coronary, cerebrovascular or peripheral artery disease. Patients with renal artery stenosis, clinically relevant valvular disease, a recent (3 months) cerebrovascular event, coronary angioplasty or by-pass surgery, congestive heart failure requiring an ACE inhibitor and coronary disease requiring a beta-blocker were excluded from being randomized. Exclusion extended to pregnant women and individuals with severe hepatic disease.

Blood pressure measurements and treatment

Both treated and untreated hypertensive patients were considered for inclusion into the trial. Untreated patients were recruited if their systolic BP was between 160 and 210 mmHg and diastolic BP was < 115 mmHg. Treated patients were recruited if their systolic BP was < 210 mmHg or diastolic BP < 115 mmHg. The recruited patients were rolled-over into one or the other arm of the trial without a run-in phase. For valsartan treatment started with 80 mg daily and for amlodipine with 5 mg daily. The dose of either drug was doubled and hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added

1
2
3 in sequential steps if BP was not reduced $< 140/90$ mmHg. Angiotensin receptor blockers
4
5 were excluded from the treatment algorithms and ACE inhibitors and calcium channel
6
7 blockers only allowed if required for conditions other than hypertension. Patients were
8
9 followed-up for 4-6 years with visits performed monthly during the initial 6 months of
10
11 treatment and at 6 months intervals thereafter. Blood pressure was measured twice by a newly
12
13 calibrated manual sphygmomanometer 24 hours post-dose with the patient being quietly
14
15 seated for 5 min at each visit.
16
17
18

19 20 ***Outcomes***

21
22
23 The primary endpoint of the study was time to first cardiac event, i.e. a composite of fatal or
24
25 non-fatal myocardial infarction, sudden cardiac death and death from revascularization
26
27 procedures or heart failure, heart failure requiring hospitalization and emergency procedures
28
29 to prevent myocardial infarction. Secondary endpoints were all events, fatal and non-fatal
30
31 stroke, myocardial infarction, hospitalized heart failure, and CV, non-CV and all-cause
32
33 mortality. An endpoint committee, blind to treatment allocation, adjudicated events.
34
35
36

37 38 ***Data availability statement***

39
40
41 The data that support the findings of this study are available from the corresponding author,
42
43 S.E.K. upon reasonable request.
44
45

46 47 ***Statistical analyses***

48
49 Because the primary endpoint was not significantly different between the two treatment
50
51 groups data were pooled for all analyses of the patients with type-2 DM (n=5250). Four
52
53 groups according to the percentage of on-treatment visits with BP $< 140/90$ mmHg up to the
54
55 occurrence of an event: $< 25\%$, 25 to 49%, 50 to 74% and $\geq 75\%$ were considered as done in
56
57 previous trials [13-14] including in the overall VALUE population [15]. The same four group
58
59
60

subdivision was used for the percentage of visits with BP < 130/80 mmHg, i.e. the target BP recommended by guidelines in a high CV risk condition [5-7]. On the assumption that the BP found at a given visit reflected the value existing during the preceding between-visit interval data were expressed as the percentage of time in which BP was reduced below the higher or lower value. For each group calculation was made of the incidence of the primary and secondary endpoints. The relative risk of each endpoint was quantified separately for the higher and lower BP target, using the Cox proportional hazard model and taking the group in which BP control covered $\geq 75\%$ of the on-treatment time as reference. To reduce the impact of potential confounders hazard ratios were adjusted for baseline covariates (age, gender, systolic BP and diastolic BP, body mass index, high serum total cholesterol [240 mg/dl or 6 mmol/L], smoking, proteinuria, history of CV events and left ventricular hypertrophy). For baseline systolic BP and diastolic BP, the 5th degree polynomials were used to capture an extended range of possible relationships between BP and events. Two-sided p-values were calculated for trends versus the subgroup with $\geq 75\%$ of the time with BP control. $P < 0.05$ was considered statistically significant without adjustment for multiplicity. Data are shown as means \pm standard deviations (SDs) or estimates with 95% confidence intervals (CIs).

Results

Baseline characteristics in relation to time achieving target < 140/90 mmHg

Table 1 shows the baseline characteristics of the patients achieving BP < 140/90 mmHg over different proportions of the on-treatment period prior to the occurrence of the primary endpoint. Systolic BP and diastolic BP were progressively greater, and most CV risk and disease factors progressively more common, from the longest to the shortest time ($\geq 75\%$ to <

1
2
3 25%) with a BP < 140/90 mmHg, with an expected concomitant progressive increase of
4
5 average on-treatment BP.
6
7

8 Fractions of smokers and fractions of study participants with coronary disease were inversed,
9
10 while heart rate, baseline antihypertensive treatment, body mass index and fraction of patients
11
12 with previous stroke or transient ischemic attack were unchanged. Results were similar when
13
14 groups were stratified according to BP values prior to the occurrence of secondary endpoints
15
16 (data not shown).
17
18

19 20 21 ***Event incidence and risk for BP < 140/90 mmHg*** 22

23
24 Both for the primary and for all secondary endpoints the *event incidence* increased
25
26 progressively as the time with BP < 140/90 mmHg decreased (Figure 1, upper panel). The *risk*
27
28 of any event also showed a steep progressive increase as the time with a BP below 140/90
29
30 mmHg decreased when adjusting the data for baseline covariates, including systolic BP and
31
32 diastolic BP values (Figure 2, upper panel).
33
34

35 36 37 ***Baseline characteristics in relation to time achieving target < 130/80 mmHg*** 38

39
40 Table 2 shows the baseline characteristics of the patients achieving BP < 130/80 mmHg over
41
42 different proportions of the on-treatment period prior to the occurrence of the primary
43
44 endpoint. Although the between-group differences were less pronounced and not invariably
45
46 significant, baseline systolic BP and diastolic BP values as well as prevalence of several CV
47
48 risk and disease factors increased progressively from the group with the longest to the group
49
50 with the shortest time at BP < 130/80 mmHg. There was an expected concomitant progressive
51
52 increase of the on-treatment average BP values.
53
54

55
56 At variance from the findings shown in Table 1, fractions with antihypertensive treatment at
57
58 baseline increased with BP control $\geq 75\%$. This was also the case for fractions of participants
59
60

1
2
3 with coronary disease but not for fractions of smokers, which was also at difference from the
4 findings in Table 1. The results were similar when the groups were stratified according to BP
5 values prior to the occurrence of secondary endpoints (data not shown).
6
7
8
9

10 ***Event incidence and risk for BP < 130/80 mmHg***

11
12
13 From the longest to the shortest time with BP < 130/80 mmHg the *incidence* of stroke
14 continued to show a progressive increase and non-CV mortality concomitantly exhibited a
15 progressive reduction. The incidence of the primary and all other CV endpoints showed a J-
16 curve pattern, i.e. an increase as the time under more intensive BP control decreased from \geq
17 75% to 50 to 74%, with a decrease as control was achieved for times shorter than 50% (Figure
18 1, lower panel). However, importantly the *risk* of all the various events did not show any
19 consistent trend from the longest to the shortest time with a BP < 130/80 mmHg when
20 adjusting the data for baseline covariates, including systolic BP and diastolic BP values
21 (Figure 2, lower panel).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

40 **Discussion**

41
42 The risk of CV morbidity and mortality as well as myocardial infarction, heart failure and
43 stroke in mostly elderly patients with the combination type-2 DM and hypertension showed a
44 progressive steep increase as the rate of BP control < 140/90 mmHg decreased from \geq 75% to
45 < 25% of the on-treatment time. There was a concomitant steep increase in the risk of these
46 events when adjusting for between-group differences in a large number of demographic and
47 clinical baseline variables. This was not the case for the different rates of BP control < 130/80
48 mmHg. For patients below these BP values, the adjusted overall morbidity and mortality risk,
49 as well as the risk of cause-specific events of cardiac disease and stroke, were unaffected by
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the frequency of BP control. Thus, while more frequent BP reductions < 140/90 mmHg were
4 highly protective, no further protection was achieved by more frequent BP reductions <
5 130/80 mmHg. Our findings provide evidence in support of BP target < 140/90 mmHg but
6
7 also against the need of pursuing an intensive BP target in middle-aged and elderly patients
8
9 averaging about 67 years with type-2 DM and hypertension, as presently recommended by
10
11 international guidelines [5-7].
12
13
14
15

16
17 Several other results of our study are noteworthy. One, in the present large subgroup of 5250
18
19 DM hypertensive patients the relationship of the higher and lower BP targets with the
20
21 incidence and adjusted risk of CV morbidity and mortality was principally similar to that of
22
23 the entire VALUE population, i.e. CV protection was achieved by reducing BP <140/90
24
25 mmHg with no further protection < 130/80 mmHg. We discuss the comparison of the DM
26
27 patients with the entire population of high-risk hypertension in VALUE in more details in a
28
29 companion article [16].
30
31
32
33

34
35 Two, in a large trial of DM patients systolic BP reduction < 120 mmHg did not show
36
37 beneficial effects on CV morbidity and mortality except for stroke, the risk of which was
38
39 reduced by 41% compared to patients remaining at SBP > 130 mmHg [4]. In post-hoc
40
41 analyses of other large scale trials including hypertensive or normotensive patients, treatment-
42
43 induced progressive systolic BP reduction to 120 mmHg or less was accompanied by no effect
44
45 or even an increase of CV events and myocardial infarction, again with a progressive
46
47 reduction in the incidence of stroke [9-11].
48
49
50

51
52 Three, only about one third of our patients with DM achieved BP < 140/90 mmHg for $\geq 75\%$
53
54 of the overall treatment duration, and in more than half of the patients this highly protective
55
56 target BP remained unachieved for half of the treatment time. This confirms that consistent
57
58 BP control is a difficult goal to reach even in the context of a randomized clinical trial, i.e.
59
60

1
2
3 when the patients are care taken by expert investigators and the follow-up is more adequate
4 than in regular clinical practice. Given the evidence that visit-to-visit BP variability may be an
5 independent CV risk factor [17-19] the inconsistency of BP control may be one of the factors
6
7 responsible for the persistently high residual risk exhibited by treated hypertensive patients
8
9
10
11
12 [20].
13
14

15 Four, it is remarkable that non-CV mortality risk is highly significantly related to improved
16 BP control over time when target BP is < 140/90 mmHg. This finding suggests that in our
17 patients with DM and high-risk hypertension, there is an extensive misclassification of CV
18 death into non-CV death. In fact, the finding mirrors the relationship between time-dependent
19 BP control and CV mortality with similar finding also for all-cause mortality.
20
21
22
23
24
25

26
27 Five, fractions of smokers and fractions of study participants with coronary disease were
28 increasing with $\geq 75\%$ of controls at BP target <140/90 mmHg. Further, fractions of
29 participants with coronary disease but not fractions of smokers also increased with $\geq 75\%$ of
30 controls at BP target <130/80 mmHg. We report these findings in middle-aged and elderly
31 patients with DM and hypertension, but we have not elucidated these findings in detail.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Possibly, coronary patients with DM and hypertension receive the utmost attention for BP control with BP lowering medication.

Study limitations

Our study had some limitations. One, only a limited number of patients achieved BP < 130/80 mmHg at rates greater than 50% or 75% of the treatment duration, which means that this target comparison involved groups of different sizes. This was particularly the case for the DM patients, in whom the low rate of intensified BP control for 50% or more of the overall treatment duration may have favored chance findings such as the lack of relationship between

1
2
3 the BP reduction and the risk of stroke compared to the overall trial population. Two, because
4
5 in post-hoc analyses comparisons involve non-randomized groups, the possibility that our
6
7 results did not depend on the achievement rates of higher or lower BP values but rather on
8
9 differences in baseline characteristics cannot be excluded. However, our estimates of CV risk
10
11 were adjusted for a large number of baseline variables, including markers of asymptomatic
12
13 hypertension mediated organ damage (left ventricular hypertrophy and proteinuria), that have
14
15 an important impact on CV risk. Three, the effect of more properly achieving higher and
16
17 lower BP targets was different, although baseline differences between groups were
18
19 qualitatively similar in either case. Four, unaccounted baseline differences are unlikely to
20
21 explain the effect of BP reductions < 140/90 mmHg on the various CV events. Thus, although
22
23 interpretation of post-hoc data requires caution, it seems reasonable to conclude that baseline
24
25 confounders did not play a major role in our results.
26
27
28
29
30

31 **Implications**

32
33
34
35 Our data suggest that in middle-aged and elderly patients with type-2 diabetes mellitus and
36
37 hypertension a more consistent achievement of blood pressure target < 140/90 mmHg leads to
38
39 a major reduction in the risk of coronary events, heart failure, and stroke, protective effects
40
41 extending to lower cardiovascular and all-cause mortality and even to non-cardiovascular
42
43 mortality. This does not occur for a more frequent control of blood pressure < 130/80 mmHg.
44
45 Thus, guidelines should not recommend using this intensive blood pressure target in middle-
46
47 aged and elderly patients with diabetes and hypertension. Our findings are in line with a
48
49 recent Cochrane analysis (21).
50
51
52
53
54
55
56
57
58
59
60

Disclosure statement

S.E. Kjeldsen has received honoraria from Merck GBaA, Sanofi and Takeda. R. Mo has received honoraria from Novartis. B. Holzhauser and D. Zappe are employees of Novartis Pharma. The other authors report no relevant conflicts of interest.

Acknowledgements

The VALUE trial (Valsartan Antihypertensive Long-Term Use Evaluation) was funded by an unrestricted grant from Novartis Pharma AG. The data file resides in the hands of the authors at Oslo University Hospital, Oslo, Norway. We are indebted to Dr. Tsushung A. Hua, PhD (diseased 2018), Unit of Biostatistics and Pharmacometrics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA for invaluable help through many years.

References

1. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet*. 1998;351:1755–1762.
2. Holman RR, Paul SK, Berthel MA, et al. Long-term follow-up after tight control of blood pressure in type-2 diabetes. *N Eng J Med*. 2008;359:1565-1576.
3. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007; 370:829–840.
4. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1575–1585.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
5. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. *Diabetes Care*. 2017;40:1273-1284
6. Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Blood Press*. 2018;27:314-340.
7. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71:1269-1324.
8. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. *BMJ*. 2016;352:i717.
9. Cooper DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. *JAMA*. 2010;304:61-68.
10. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). *JACC*. 2012;59:74-83.
11. Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. *JACC*. 2014;64:588-597.
12. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*. 2004;363:2022-2031.
13. Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. *Hypertension*. 2007;50:299-305.
14. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). *Circulation*. 2011;124:1727-1736.

- 1
2
3 15. Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-
4 treatment blood pressures in the hypertensive patients of the VALUE trial. *Eur Heart*
5 *J.* 2016;37:955-964.
6
7
- 8 16. Olsen E, Holzhauer B, Julius S et. al. Cardiovascular outcomes at recommended blood
9 pressure targets in middle-aged and elderly patients with type-2 diabetes mellitus
10 compared to all middle-aged and elderly hypertensive study participants with high
11 cardiovascular risk. Submitted.
12
13
- 14 17. Mehlum MH, Liestøl K, Kjeldsen SE, et al. Blood pressure variability and risk of
15 cardiovascular events and death in patients with hypertension and different baseline
16 risks. *Eur Heart J.* 2018;39:2243-2251.
17
18
- 19 18. Mehlum MH, Liestøl K, Wyller TB, et al. Blood pressure variability in hypertensive
20 patients with atrial fibrillation in the VALUE trial. *Blood Press.* 2019;28:77-83.
21
22
- 23 19. Mehlum MH, Liestøl K, Kjeldsen SE, et al. Blood pressure–lowering profiles and
24 clinical effects of angiotensin receptor blockers versus channel blockers.
25 *Hypertension.* 2020;75:1584-1592.
26
27
- 28 20. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome
29 incidence in hypertension. 3. Effects in patients at different levels of cardiovascular
30 risk. Overview and meta-analyses of randomized trials. *J Hypertens.* 2014;32:2305–
31 2314.
32
33
- 34 21. Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people
35 with hypertension and cardiovascular disease. *Cochrane Database Syst Rev.* 2020 Sep
36 9;9:CD010315. doi: 10.1002/14651858.CD010315.pub4. PMID: 32905623.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends to figures

Figure 1

Incidence of morbid and fatal events in groups of diabetic patients divided according to the proportion of the overall treatment duration ($< 25\%$ to $\geq 75\%$) in which BP was reduced $< 140/90$ mmHg (upper panel) or $< 130/80$ mmHg (lower panel) prior to the occurrence of an event. N refers to the number of patients in each group. CV: cardiovascular; MI: myocardial infarction; CHF: congestive heart failure.

Figure 2

Percent (and 95% CI) change in the risk of events according to the proportion of time in which BP was reduced $< 140/90$ mmHg (upper panel) or $< 130/80$ mmHg (lower panel) in groups of diabetic patients. The group in which these BP targets were achieved for $\geq 75\%$ of the time is taken as reference and shown by the empty circle (minor variations in “n” as some endpoints were composite and primary and other endpoints secondary). Data were adjusted for both baseline covariates and achieved average systolic BP and diastolic BP. P values refer to trend. Other symbols as in Figure 1.

1
2
3 **Fig. 1 and Fig. 2 follow after Table 1 and Table 2**
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Table 1 – Baseline characteristics of the 4 groups of *diabetic* patients in which treatment reduced BP below 140/90 mmHg for different proportions (from < 25% to ≥ 75%) of the overall duration of treatment.


	< 25%	25% - 49%	50% - 74%	≥ 75%	P (trend)
n	1688	946	1042	1574	
Females (%)	47.0	46.7	42.7	40.7	<0.0001
Age (years)	67.6 ± 7.7	68.0 ± 8.0	67.0 ± 7.8	66.1 ± 8.0	<0.0001
Caucasians (%)	89.2	87.4	86.2	81.2	<0.0001
SBP (mmHg)	166.0 ± 17.6	158.0 ± 17.0	153.0 ± 16.7	146.0 ± 17.1	<0.0001
DBP (mmHg)	88.8 ± 10.9	87.1 ± 10.6	86.6 ± 10.6	85.0 ± 10.4	<0.0001
Heart rate (beats/min)^o	73.0 ± 13.8	72.7 ± 13.6	72.5 ± 13.8	72.3 ± 13.7	0.523
Antihypertensive treatment (%)	93.9	93.3	93.7	94.2	0.728
Body mass index (kg/m²)	30.1 ± 5.4	30.1 ± 5.3	29.9 ± 5.6	29.7 ± 5.5	0.088
Smoking (%)	17.5	19.0	19.6	24.7	<0.0001
Proteinuria (%)	32.8	28.8	26.1	24.0	<0.0001
High serum creatinine (%)	4.9	5.3	3.2	1.9	<0.0001
High total cholesterol (%)	32.6	29.0	28.9	25.0	<0.0001
Left ventricular hypertrophy (%)[*]	7.5	5.5	4.4	3.1	<0.0001
Coronary disease (%)	35.7	38.7	39.6	45.6	<0.0001
Stroke / TIA (%)	15.0	17.1	17.7	15.7	0.508
Peripheral artery disease (%)	13.7	14.3	11.2	10.0	<0.0003
On-treatment mean SBP (mmHg)	156.2 ± 11.0	143.4 ± 4.0	137.9 ± 3.7	131.0 ± 5.6	<0.0001
On-treatment mean DBP (mmHg)	84.2 ± 8.3	80.4 ± 6.5	79.4 ± 5.9	77.5 ± 5.6	<0.0001

Data are shown as means ± SD or %. ^oby EKG; ^{*} EKG, strain pattern; Data from all randomized patients without GCP deficiencies and missing BP values; S: systolic; D: diastolic; TIA: transient ischemic attack; High serum creatinine: ≥ 150 μmol/L; High total cholesterol: ≥ 240 mg/dL (6 mmol/L)

Table 2 – Baseline characteristics of the 4 groups of *diabetic* patients in which treatment reduced BP below 130/80 mmHg for different proportions (from < 25% to ≥ 75%) of the overall duration of treatment.

	< 25%	25% - 49%	50% - 74%	≥ 75%	P (trend)
n	4348	516	245	141	
Females (%)	44.8	40.7	43.3	35.5	0.017
Age (years)	67.2 ± 7.9	66.8 ± 8.0	66.7 ± 7.7	66.8 ± 8.4	0.57
Caucasians (%)	86.8	82.0	83.7	74.5	<0.0001
SBP (mmHg)	159.0 ± 18.0	147.0 ± 16.9	143.0 ± 17.7	134.0 ± 16.6	<0.0001
DBP (mmHg)	88.0 ± 10.5	83.0 ± 10.6	81.6 ± 10.8	77.8 ± 11.0	<0.0001
Heart rate (beats/min)^o	72.8 ± 13.7	71.8 ± 13.8	72.4 ± 13.6	71.3 ± 13.3	0.25
Antihypertensive treatment (%)	93.3	96.1	95.9	97.9	0.0005
Body mass index (kg/m²)	29.9 ± 5.4	30.0 ± 5.8	30.2 ± 5.8	29.5 ± 5.7	0.67
Smoking (%)	20.2	20.0	22.9	22.0	0.49
Proteinuria (%)	28.8	27.1	21.2	23.4	0.014
High serum creatinine (%)	4.0	3.5	0.4	2.8	0.029
High total cholesterol (%)	30.2	25.2	20.8	19.1	<0.0001
Left ventricular hypertrophy (%)*	5.3	5.0	4.9	3.5	0.49
Coronary disease (%)	37.6	47.9	52.7	60.3	<0.0001
Stroke / TIA (%)	15.7	19.2	15.9	17.7	0.096
Peripheral artery disease (%)	12.3	11.8	11.4	12.8	0.74
On-treatment mean SBP (mmHg)	145.7 ± 11.7	132.0 ± 4.1	127.0 ± 3.6	120.5 ± 5.3	<0.0001
On-treatment mean DBP (mmHg)	81.9 ± 7.1	75.8 ± 5.2	73.8 ± 4.6	70.6 ± 5.0	<0.0001

Symbols and explanations as in Table 1.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

